Quarterly & Annual Financial Results

Glenmark Pharmaceuticals Reports Strong FY26 Growth; Revenue Surges 27.5%, AbbVie Licensing Deal Strengthens Innovation Pipeline

NSE

glenmark

BSE

532296

Glenmark Pharmaceuticals reported a strong FY26 performance with consolidated revenue growing 27.5% YoY to ₹16,982.5 crore, supported by robust growth across North America, Europe, and Emerging Markets. EBITDA increased to ₹4,572.4 crore with a margin of 26.9%, while PAT stood at ₹1,362 crore. The year was highlighted by the landmark AbbVie licensing deal for ISB-2001, expansion of the oncology portfolio, continued global momentum of RYALTRIS®, and strengthening of the respiratory franchise in the U.S.

PRICE-SENSITIVE TRIGGER

Event: Announcement of Q4 FY26 and FY26 audited financial results along with operational and strategic business updates.

Type: Quarterly & Annual Financial Results

Impact: Positive

Immediate Effect: Strong earnings growth, improved profitability, successful monetization of innovation assets, and continued expansion across key international markets strengthen business visibility and investor confidence.

Key Metrics:

Q4 FY26 Revenue: ₹3,770.6 crore | YoY Growth: +15.8%
Q4 FY26 EBITDA: ₹762.6 crore
Q4 FY26 EBITDA Margin: 20.2%
Q4 FY26 PAT: ₹301.3 crore
Q4 FY26 PAT Margin: 7.6%
FY26 Revenue: ₹16,982.5 crore | YoY Growth: +27.5%
FY26 EBITDA: ₹4,572.4 crore
FY26 EBITDA Margin: 26.9%
FY26 PAT: ₹1,362.0 crore
FY26 PAT Margin: 7.8%

Highlight:

FY26 consolidated revenue rose 27.5% YoY to ₹16,982.5 crore, driven by strong international growth and the AbbVie licensing transaction for ISB-2001.

What Happened ?

Glenmark Pharmaceuticals delivered a strong FY26 performance across financial and operational metrics. Growth was supported by expanding respiratory and oncology portfolios, strong performance in North America and Europe, continued commercialization of RYALTRIS®, and strategic innovation-led partnerships.

The company signed a landmark licensing agreement through Ichnos Glenmark Innovation (IGI) with AbbVie for ISB-2001, receiving a USD 700 million upfront payment and securing a potential deal value of up to USD 1.925 billion plus royalties.

The company also strengthened its oncology pipeline through licensing agreements with Hengrui Pharma and Hansoh Pharma, expanded its respiratory franchise in the U.S., and achieved significant progress in branded and specialty products across global markets.

Key Details

Operational Performance & Strategic Developments:

North America revenue increased 29.4% YoY during Q4 FY26.
Europe business grew 21.4% YoY in Q4 FY26.
Emerging Markets recorded 13.7% YoY growth during Q4 FY26.
India formulation business revenue increased 8.2% YoY.
India business grew 1.5x faster than overall IPM growth according to IQVIA.
RYALTRIS® achieved more than 50% growth in global secondary sales during FY26.
RYALTRIS® received approvals and launches in China and Thailand.
Glenmark initiated direct commercialization of RYALTRIS® in the U.S.
Oncology portfolio expanded through Trastuzumab Rezetecan and Aumolertinib licensing deals.
U.S. respiratory franchise strengthened through approval of generic Flovent® HFA and Fluticasone Propionate Nasal Spray OTC.
Monroe injectable manufacturing facility received U.S. FDA EIR with VAI classification, enabling restart of commercial manufacturing.
Glenmark launched GLIPIQ® (Semaglutide) for Type-2 Diabetes in India.
TEVIMBRA® and BRUKINSA® gained strong early market acceptance in India.
WINLEVI® received EU approval and continued commercial expansion in Europe.

Note:

The AbbVie transaction significantly validates Glenmark’s innovation platform and provides both financial flexibility and future royalty potential from ISB-2001 commercialization.

Risk Analysis

Summary:

While operating performance remains strong, Glenmark continues to face regulatory, competitive, and litigation-related risks across global markets.

Key Risks:

Revenue growth in North America partly benefited from deferred recognition related to the ISB-2001 licensing transaction.
Generic pharmaceutical pricing pressure remains an industry-wide challenge.
Regulatory approvals remain critical for future respiratory and oncology launches.
Ongoing antitrust litigation in the U.S. generic pharmaceutical industry continues to require monitoring.
Glenmark USA agreed to a proposed settlement of approximately USD 29.6 million with state attorneys general, subject to court approval.
Commercial success of newly licensed oncology assets remains dependent on regulatory approvals and execution.

Worst Case Scenario:

Delays in commercialization, regulatory setbacks, or slower-than-expected adoption of specialty and oncology products could impact future growth expectations and profitability.

Risk Level: Medium

Company Commentary

Management described FY26 as a defining year in Glenmark’s evolution.
The AbbVie partnership validates the company’s innovation capabilities and global scientific relevance.
The company remains focused on differentiated science, disciplined execution, and sustainable value creation.
RYALTRIS®, oncology partnerships, and respiratory product launches are expected to remain key future growth drivers.
Glenmark intends to combine the scale of a global pharmaceutical company with the ambition of an innovation-driven organization.
Management remains confident about long-term growth opportunities across branded, specialty, respiratory, oncology, and innovative biologics businesses.

Official Exchange Filing: Glenmark Pharmaceuticals Limited